🔴 Corcept Therapeutics is trading 4.6% down today on profit-taking after last week’s 27% post-earnings surge

Corcept Therapeutics is trading 4.6% down at $109.25 as investors take profits following a sharp rally driven by a recent earnings beat and a major revenue guidance hike.

• The stock jumped roughly 27% on July 30, 2026, after the company raised its 2026 revenue guidance to $1.1–$1.2 billion from approximately $950 million.
• The rally was also supported by the oncology launch of Lifyorli; today's move is viewed as consolidation rather than a reaction to new negative company-specific news.